Please login to the form below

Not currently logged in
Email:
Password:

ZP2929

This page shows the latest ZP2929 news and features for those working in and with pharma, biotech and healthcare.

Boehringer switches diabetes candidate in Zealand collaboration

Boehringer switches diabetes candidate in Zealand collaboration

Will swap ZP2929 for another GLP-1 receptor agonist. Boehringer Ingelheim has decided to drop the diabetes and obesity drug candidate ZP2929 it has spent nearly three years developing with Zealand ... No specific reason was given for Boehringer's

Latest news

  • Drug delivery

    Other deals of note were Boehringer Ingelheim's (BI) agreement with Zealand Pharma for rights to its ZP2929 - GLP1 receptor agonists against type 2 diabetes and obesity, further building the ... DPP-IV inhibitors (T2D) patent estate. Divestment. 609.

  • Boehringer and Zealand focus on diabetes

    Boehringer Ingelheim will obtain global development and commercialisation rights to ZP2929, Zealand Pharma's lead glucagon/GLP-1 dual agonist drug candidate. ... Zealand Pharma will be eligible to receive payments for ZP2929 and could receive additional

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics